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Treatment for Chagas disease with currently available medications is recommended universally only for acute cases (all ages)
and for children up to 14 years old. TheWorld Health Organization, however, also recommends specific antiparasite treatment
for all chronic-phase Trypanosoma cruzi-infected individuals, even though in current medical practice this remains controver-
sial, andmost physicians only prescribe palliative treatment for adult Chagas patients with dilated cardiomyopathy. The present
opinion, prepared by members of the NHEPACHA network (Nuevas Herramientas para el Diagnóstico y la Evaluación del Paci-
ente con Enfermedad de Chagas/New Tools for the Diagnosis and Evaluation of Chagas Disease Patients), reviews the paradigm
shift based on clinical and immunological evidence and argues in favor of antiparasitic treatment for all chronic patients. We
review the tools needed to monitor therapeutic efficacy and the potential criteria for evaluation of treatment efficacy beyond par-
asitological cure. Etiological treatment should now bemandatory for all adult chronic Chagas disease patients.
There are an estimated 8 million chronic Chagas disease (CD)patients in Latin America (1), a large proportion of whom do
not receive specific antiparasite treatment, and a growing infected
population in the United States, Canada, and Europe (2). Antip-
arasitic treatment for Chagas disease (CD) is recommended uni-
versally for acute cases and for children up to 14 years old in most
countries (3). Despite the inclusion of chronic patients in the
guidelines, most doctors only prescribe symptomatic treatment of
cardiomyopathy and digestive symptoms, avoiding antiparasitic
drugs. At a meeting of clinical CD experts held in 1983, the use of
etiological treatment for chronic stages was not recommended,
pendingmore solid evidence of its efficacy (4) and of autoimmune
mechanism involvement (5). Natural and elicited immunoglobu-
lins and effector immune cells produced or modified during
Trypanosoma cruzi infection can directly or indirectly affect heart
tissue. There is no evidence that any putative autoimmune mech-
anisms, which may be secondary aggravating factors in the pro-
gression to cardiomyopathy, are primary causes of the chronic
pathology (6). It is unclear, in addition, whether autoimmune
reactions can be avoided if the infection is prevented or controlled
(7), although it has been experimentally demonstrated that elim-
ination of the parasite results in the reduction or elimination of
autoimmune responses in the chronic phase of infection (8, 9).
In addition to neglecting adult chronic patient treatment by
adopting the 1983 recommendations, the lack of even a tentative
recommendation had a negative impact on the chronic patients’
perceptions regarding their illness. These patients are labeled as
“chagasic” and not simply as T. cruzi-infected persons, leading to
social stigma and negative economic and psychological effects
from carrying a lethal, cureless, and disabling disease (10). A sim-
ilar conflict between infection and disease existed for AIDS and
leprosy. Chronic progression in both cases, similar to that in CD,
evolves differentially in each patient, leading to a shift in current
clinical management to the use of pathogen-specific treatments
(3).
Scientific evidence regarding the role of the parasite, Trypano-
soma cruzi, as a stimulus and trigger for tissue damage has accu-
mulated over the last 2 decades, providing a solid basis to recon-
sider antiparasitic treatment for chronic adult patients. The
present article reviews the evidence and presents arguments for
antiparasitic treatment of adult chronic patients, representing the
opinion of clinical and biomedical scientists of the NHEPACHA
network and coinciding with international guidelines that now
recommend offering treatment to these patients (3, 11, 12).
PATHOGENESIS OF CHRONIC CHAGAS DISEASE: CHRONIC
PERSISTENCE OF THE PARASITE?
Following the acute phase ofT. cruzi infection, CD patients evolve
a chronic phase which is initially asymptomatic (indeterminate
form of CD). This form of CD is defined by T. cruzi infection
(positive parasitological and/or serological tests), the absence of
clinical disease symptoms, and normal electrocardiogram (EKG),
thorax radiography, and colonic/esophageal imaging tests. How-
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ever, around 30% to 40% of chronically infected individuals will
develop symptomatic disease over time (13). Biomarkers to follow
each patient’s evolution are currently being developed, assessed,
and standardized. Several studies have highlighted the key role of
myocardial inflammation in the progressive fibrotic cardiomyop-
athy of chronic cardiac CD (14). Evidence for chronic persistence
of infective parasites after the acute infection, both in areas where
T. cruzi is endemic and where it is not, includes vertical transmis-
sion or transfusion and transplant transmission, which only occur
if there are viable parasites in chronically infected mothers or
blood/transplant donors (15, 16). In addition, chronic persistence
is evident from clinical reactivations of immune-depressed pa-
tients or transplanted or HIV-infected individuals (17, 18), by
isolation of parasites through hemoculture of samples from
chronically infected patients, and by detection of parasites in bug
feces following xenodiagnosis. Parasites can be detectedmost sen-
sitively in blood and tissues using molecular techniques (19) and
have been documented in cardiac inflammatory tissues (20).
The pathogenesis of chronic CD is currently considered mul-
tifactorial, with as-yet poorly understood complex host-pathogen
interactions. Several potential autoimmune mechanisms have
been described (21), and good reviews and critiques of prevailing
theories are available (22, 23). Although there is no doubt regard-
ing the existence of an inflammatory immune response in CD,
there is no conclusive experimental evidence that autoimmunity
plays a significant role in its pathogenesis (7). Additional factors
which may also play a role in chronic CD are microvascular dis-
turbances and neurogenic lesions producing dysautonomy (24).
Overall, the prevailing evidence indicates that parasite persis-
tence is fundamental for triggering and sustaining pathogenic
processes (25).
WHAT IS CONSIDERED EFFICACY: A LOWER PARASITE
BURDEN OR PARASITE CLEARANCE?
Although the treatment goal for infectious diseases is or should be
pathogen elimination, there are other equally important thera-
peutic outcomes to be considered (26). Control and reduction of
the pathogen burden are well-recognized strategies for some in-
fections, such as AIDS, which is now a classic example of a lethal
infection which can convert into a chronically controlled disease
with the administration of appropriate treatment.
Numerous studies in animal models and humans have re-
ported the efficacy of parasitic treatment in both the acute and
chronic phase of CD (8, 9, 27, 28), with two randomized studies
having demonstrated the efficacy of benznidazole treatment in
children (29, 30). Furthermore, other experimental studies have
demonstrated a strong treatment impact on many immune re-
sponse parameters, and these findings are consistent with parasite
elimination or reduction (31, 32).One previous report and several
subsequent nonrandomized studies have shown improved clinical
and serological evolution for treatment with benznidazole com-
pared with the same parameters in untreated chronic patients (26,
33–37). Numerous subsequent studies and evidence supporting
etiologic treatment of chronic CDare summarized elsewhere (27),
while Table 1 summarizes the results of etiologic treatment in
chronic patients from four nonrandomized studies (38). These
latter studies demonstrate better clinical evolution in antiparasite-
treated patients. An association between clinical evolution and
negative seroconversion has also been analyzed in these previous
studies, as in a recent publication that reported 107 chronic adult
patients with cure criteria (39).
Two randomized trials are in the process of comparing ben-
znidazole to placebo in chronic patients. The first, including pa-
tients with or without mild heart disease, conducted in Argentina
(TRAENA) and terminated in 2012, is currently being analyzed
(40). The other is a multicenter study (BENEFIT) that should be
completed by 2014 (41) and will provide evidence regarding the
evolution of advanced or mild heart disease in chronic patients
treated with antiparasitic drugs. The evolution of individuals with
irreversible myocardial damage and, hence, at the clinical end-
point for trial evaluation may not be the same as for those who
have not yet developed cardiomyopathy when they are each given
antiparasitic treatment.
TREATMENT MONITORING
Antiparasitic treatment efficacy in Chagas disease can only be
measured currently using anti-T. cruzi antibody titers and/or by
parasite detection in blood. A therapeutic failure is defined by the
persistence of the parasite, detected using different methods, such
as PCR, while treatment success would be measured by the ab-
sence or reduction of antibody titers. However, a reduction in T.
cruzi-specific antibody titers often takes many years, rendering
measurement of treatment success insensitive and lengthy.
A long-term follow-up study using qualitative PCR before and
after treatment with benznidazole, conducted in a country where
CD is not endemic (42), demonstrated two key findings. Sixty-
eight percent of adults with chronic Chagas disease were PCR
positive prior to treatment, and of these, 100% converted to PCR
TABLE 1 Results of nonrandomized studies with etiological treatment for patients with chronic Chagas disease, showing the relationship between
clinical and serological evolutiona
1st author, yr (reference)
No. of patients:
No. of patients (treated/not
treated) that had: % of patients:







Viotti, 1994 (33) 131 70 0/4 2/17 88 19 6
Gallerano, 2000 (35) 535 668 14/34 4/18 78 5 Data not available
Viotti, 2006 (37) 283 283 5/16 4/14 71 15 6
Fabbro De Suasnábar, 2000 (34) 54 57 4/16 75 37 Data not available
Avg 6/17 3/16 78 19 6
a Treatment was with benznidazole except for reference 35, which reports on 309 patients treated with alopurinol, 130 treated with benznidazole, and 96 treated with nifurtimox.
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negative immediately after treatment. Additionally, sustained
PCR-negative results were observed in 90% of treated patients
after 1 year posttreatment. Standardized qualitative PCR for the
assessment of the impact of parasitic load on the overall treatment
response is now available (43) and is being used in ongoing pre-
clinical and clinical studies. These studies will clarify the value of
quantitative and qualitativeT. cruziDNAmeasurements formon-
itoring therapeutic response and their association with clinical
outcomes (40, 41).
Changes in various biochemical (44) and nonconventional se-
rological and immune parameters detected shortly after ben-
znidazole treatment may also be used for evaluating therapeutic
efficacy. Following benznidazole treatment, there is a reduction of
several markers, such as (i) anti-T cruzi gamma interferon (IFN-
)-producing cells (45), (ii) T. cruzi antigen-specific antibody ti-
ters detected using nonconventional serology (multiplex) (26),
and (iii) seroreactivity against specific recombinant antigens
(complement regulatory protein, recombinant trans-sialidase, or
kinetoplastid antigen) (46, 47).
The tools available to assess treatment impact in adult chronic
patients, although not always accessible in the medical practice,
can be summarized as follows.
• Clinical stability, which has low sensitivity but high signifi-
cance, should be evaluated using clinical signs and symp-
toms and complementary methods like EKG and echocar-
diogram and should always accompany the other markers
for treatment efficacy.
• Seroconversion using conventional serology is often long-
term or incomplete, although it continues to be a standard
for follow-up.
• Changes in specific anti-T. cruzi T cell responses and IFN-
production after treatment may correlate with the immune
status prior to treatment and with the efficacy of treatment.
ADVERSE EFFECTS OF ANTIPARASITIC TREATMENT
Both benznidazole and nifurtimox, the only drugs currently avail-
able for treatment, can have variable adverse effects. Adults are
more affected than children, and a proportion of treated individ-
uals must discontinue treatment due to severe adverse events (ad-
verse drug reactions [ADR]). Severe adverse events, similar to the
incidence of ADR like Stevens-Johnson syndrome for other drugs,
occur in an estimated one in 3,000 treated patients (48). Using a
rabbit model, a high dose of benznidazole can provoke an in-
creased risk of lymphoma. However, in humans and with the
doses used for Chagas treatment, no such risk has been detected in
adult cohorts with long-term follow-up (49).
Strict supervision of patients is required to manage ADR with
the aforementioned drugs. The risk of adverse effects and lack of
experience in ADR prevention and management, especially in
adults, often affects physician compliance for treatment (physi-
cian opposition). The development of more-effective and safe
drugs is a clear target for improved patient outcome and for clin-
ical management. Fortunately, the currently available drugs can
be used in all T. cruzi-infected adults at least until 50 years of age
with careful follow-up by attending clinical staff.
CONCLUSIONS
Chagas is a major neglected disease. For years, the hypothesis that
chronic Chagas disease has an autoimmune origin has held back
basic research and the development ofmore effective antiparasitic
drugs and, more importantly, has led to the failure to treat most
FIG 1 Comparison of concepts belonging to the old and the new paradigms for chronic Chagas disease. Relevant references are given in parentheses.
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chronic adult patients. The lack of recognition of the important
role of parasite persistence for the development of lesions and
clinical presentations is only one of the current barriers to more
effective clinical management of CD. From an integrated perspec-
tive, appropriate follow-up care for chronic patients and the de-
velopment of clinical trials for new drug candidates will require
appropriate early follow-up and surrogate markers for cure. The
evidence-based paradigm shift (Fig. 1) that supports etiological
treatment of chronic patients will require the development of
novel marker tools. Whereas there has been clear recognition of
the shift in the treatment paradigm by academia for several years,
public health and clinical care communities have lagged in recog-
nizing and adopting this evidence. The greatest challenge now is
how to change themindset and habits of health professionals who
are biased by the old paradigm.
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